| Buprenorphine or Buprenorphine/ Naloxone (n= 18) | Methadone (n= 18) | Group or time point comparison p-values |
---|---|---|---|
Opioid drug, dose (M ± SD (range) ) |  |  |  |
T2 | 22 ± 5 mg ( 10 - 28 mg) | - | T2 vs. T3, ns |
T3 | 21 ± 6 mg ( 6 - 30 mg) | - |  |
T2 | - | 119. ± 33 mg (80 - 180 mg) | T2 vs. T3, ns |
T3 | - | 129 ± 33 mg (75 - 180 mg) |  |
Participants using BZD medication | Â | Â | Â |
T2/T3 | 78%/67% | 89%/94% | ns/ns |
BZD dose at T2 (M ± SD (range)) | 20 ± 16 mg (0 - 60 mg) | 21 ± 16 mg (0 - 70 mg) | T2 vs. T3, ns ns |
BZD dose at T3 (M ± SD (range)) | 16 ± 14 mg (0 - 40 mg) | 20 ± 10 mg (0 - 40 mg) | ns T2 vs. T3, ns |
Number of other medications with possible cognitive effects a | Â | Â | Â |
T2/T3 (M ± SD ; (range)) | 1.8 ± 1.1 (0 - 3) | 2.2 ± 0.7 (1 -4) | ns |
 | 1.9 ± 1.4 (0 - 4) | 2.0 ± 1.0 (1 - 4) | ns |
 |  |  | T2 vs. T3, ns |